Ubamatamab
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Ubamatamab
- anti muc16 cd3 bite antibody regn4018
- ANTI-MUC16/CD3 BITE ANTIBODY REGN4018
- bispecific t cell engager antibody regn4018
- BISPECIFIC T-CELL ENGAGER ANTIBODY REGN4018
- muc16xcd3 bispecific t cell engager regn4018
- MUC16XCD3 BISPECIFIC T-CELL ENGAGER REGN4018
- regn 4018
- REGN-4018
- regn4018
- Regn4018
- REGN4018
- ubamatamab
- Ubamatamab
- ubamatamab [INN]
- UBAMATAMAB [USAN]
- Ubamatamab [WHO-DD]
- ubamatamab inn
- ubamatamab usan
- ubamatamab who dd
- CAS registry numbers
- 2305629-50-7
- ChEMBL ID
- CHEMBL4594595
- FDA ingredient codes (UNII)
- 6BUL1G4D60
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mab
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003893
- Subject identifier
- D010051
- Condition
- Fallopian Tube Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0002158
- Subject identifier
- D005185
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0003893
- Condition identifier
- MONDO_0002715
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006260
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008170
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0017387
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021068
Trial references
- NCT03564340
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Glycosylation sites (N)
- Sequence
- Asn-293'''' $ Asn-300
- Component
- Heavy chain B
- Type
- Protein
- Sequence
- QVQLVESGGGLVKPGGSLRLSCAASGFTFSNYYMSWVRQAPGKGLEWISYISGRGSTIFYADSVKGRITISRDNAKNSLFLQMNSLRAEDTAVYFCVKDRGGYSPYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
- Component
- Light chain
- Type
- Protein
- Sequence
- DIQMTQSPSSLSASVGDRVTITCRASQSISTYLNWYQQKPGKAPKLLIYTASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 135'-195' $ 135'''-195''' $ 131''-215''' $ 138-215' $ 144''-200'' $ 151-207 $ 223''-230 $ 226'-233 $ 257''-317'' $ 264-324 $ 363''-421'' $ 370-428
- Component
- Glycosylation sites (N)
- Sequence
- Asn-293'' $ Asn-300
- Component
- Sequence: REGN5458 Heavy Chain X'' (anti-CD3)
- Type
- Protein
- Sequence
- EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYSMHWVRQAPGKGLEWVSGISWNSGSKGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKYGSGYGKFYHYGLDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNRFTQKSLSLSPGK
Related records
Trials (7)
- A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Compassionate Use of Ubamatamab
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
- Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
- Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
In development for (3)
- Fallopian tube cancer Phase 1
- Neoplasm Phase 1
- Ovarian neoplasm Phase 1